AEGIS is a Marie Skłodowska -Curie Innovative Training Network (ITN) for early stage researchers (ESR) funded by the European Commission under the H2020 Programme the EU framework programme for research and innovation.

The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cross-disciplinary and structured curriculum for doctoral students in the European Research Area by establishing a unique training platform for the next generation of European researchers in early drug discovery. A significant added value is provided through networking with key European pharmaceutical companies. A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation.


The expected impact of the AEGIS project includes


  1. interdisciplinary training of a new generation of researchers, providing them with the required scientific expertise and soft skills to become future leaders in integrated drug discovery,
  2. the provision of innovative methods for faster, cost-effective design of ligands and target validation in Early Drug Discovery, thereby advancing the utility and impact of rational structure-based approaches,
  3. development of lead compounds for prevalent and emerging diseases threatening human health,
  4. promoting an open and innovative research environment by networking of academic and industry groups and
  5. forming a sustainable network of academic and industrial partners involving ESRs and experienced researchers beyond AEGIS.